{
  "id": 13956068,
  "title": "Nigeria: Fidelis Ayebae's Fidson Takes Nigeria's Healthcare Story Global",
  "url": "https://urgent.news/2026/10/12/nigeria-fidelis-ayebaes-fidson-takes-nigerias-healthcare-story-global",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T12:45:20.000Z",
  "source": {
    "name": "AllAfrica Health",
    "slug": "allafrica-health",
    "url": "https://allafrica.com/stories/202610120440.html"
  },
  "original_language": "en",
  "account": "Nigeria's Fidson Healthcare Plc, founded by Fidelis Ayebae, has been chosen to develop and manufacture a generic version of Roche's influenza antiviral drug, baloxavir marboxil. This selection places the company among a select group of global manufacturers participating in a Medicines Patent Pool program. Ayebae's journey to this achievement began with a non-traditional academic background - a Higher National Diploma in Civil Engineering followed by an Advanced Diploma in Business Administration, interspersed with years at Citibank before founding Fidson in 1995.\n\nThis diverse educational base has contributed to Fidson's success in manufacturing indigenous antiretroviral drugs for HIV, proton pump inhibitors, and complex infusion formats, solidifying its credibility for international deals. The company became the first Nigerian pharmaceutical entity to surpass N100 billion in revenue, eventually reaching over N119 billion. Such significant revenue growth is not achieved overnight but is the result of years of investment in manufacturing facilities, regulatory systems, and personnel.\n\nFidson's international footprint expanded through partnerships with Japan's Ohara Pharmaceutical Company for an oncology expansion and three Chinese consortiums for an HIV-focused manufacturing hub in the Lekki Free Trade Zone. Each partnership has bolstered the company's reputation, which global regulators now rely on. Under the Roche agreement, Fidson will receive technical information and reference materials to help secure regulatory approval, aiming to bring baloxavir marboxil to eligible markets at a lower cost. Fidelis Ayebae was recognized with the Nigeria Academy of Pharmacy's Lifetime Achievement Award in 2025, making him the youngest recipient of this honor. Interestingly, Ayebae was the first non-pharmacist admitted into the Pharmaceutical Society of Nigeria's Hall of Honorary Membership. AllAfrica, the news organization responsible for publishing this report, aggregates reports from over 90 news organizations and 500 other institutions, presenting a diverse range of perspectives on global events.",
  "summary": "[This Day] Fidson Healthcare Plc has been selected to develop and manufacture a generic version of Roche's influenza antiviral drug, baloxavir marboxil, through a licensing arrangement backed by the Medicines Patent Pool. The deal places founder Fidelis Ayebae's company among a small group of global manufacturers chosen for the programme.",
  "key_points": [
    "Fidson Healthcare Plc develops generic baloxavir marboxil for Roche",
    "Fidelis Ayebae, founder, has non-traditional engineering-business background",
    "Fidson becomes first Nigerian pharma to exceed N119 billion in revenue"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}